Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesQualitative or Semiquantitative ImmunoassaysCPT cpt-86304-ca-125-tumor-marker-quantitative-assay
    Ask Trek AI about this page

    CPT 86304: Quantitative CA 125 Tumor Marker Assay

    CPT code 86304 describes a quantitative laboratory assay to measure the cancer tumor antigen CA 125 in serum or other body fluids, used to evaluate and monitor tumor marker levels associated with pancreatic and other malignancies; service type: quantitative laboratory test; typical site of service: clinical laboratory or hospital laboratory.

    For related coverage guidance, see recent payer policy updates: Allergen Subcutaneous Immunotherapy (SCIT), Allergy Testing, Including Selected Blood, Serum and Cellular Testing and Toxicity Testing Corporate Medical Policy, Allergy and Sensitivity Tests of Uncertain Efficacy.

    Customize your policy alerts

    Sign up for cpt 86304 policy alerts

    Get alerted when payer policies referencing 86304 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 6

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 58-year-old female with a history of chronic pancreatitis presents with progressive abdominal pain and unintentional weight loss. The ordering clinician requests a serum tumor marker panel to assist with evaluation for possible pancreatic malignancy. A phlebotomist obtains a peripheral blood specimen which is transported to the clinical laboratory. The laboratory technologist performs a quantitative immunoassay for cancer antigen CA 125 using the serum sample. Results are reviewed and reported in the electronic medical record; elevated values are used alongside imaging, histopathology, and clinical findings to support diagnosis, staging, or disease monitoring.

    Typical site of service: outpatient clinical laboratory or hospital laboratory. Service type: quantitative laboratory immunoassay for tumor marker measurement. Typical workflow: specimen collection, accessioning, centrifugation, analysis on validated instrumentation, result verification by a qualified laboratorian, and reporting to the ordering provider.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    36415Collection of venous blood by venipunctureSpecimen collection required prior to performing the 86304 assay.
    80053Comprehensive metabolic panelCommon accompanying laboratory panel ordered alongside tumor marker tests to assess organ function.
    85025Complete blood count (CBC) with automated differentialFrequently ordered in oncology evaluations to assess hematologic status during diagnosis and treatment.
    88305Level IV surgical pathology, gross and microscopic examinationTissue pathology that provides definitive diagnosis complementary to tumor marker results.
    81002Urinalysis, non-automated, without microscopyAncillary test sometimes ordered in the evaluation of systemic disease and treatment monitoring.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    1PModifier 1P is a Category II performance measure exclusion modifier used to indicate that a patient’s medical condition prevented performance of the action specified by a Category II quality measure…- Use modifier 1P only with Category II (quality reporting) codes when the specific measure’s reporting instructions explicitly allow a medical-reason exclusion; it marks the patient as medically…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207R00000X
    207L00000X
    163W00000X
    207K00000X
    364SA2200X
    364SH1100X
    275N00000X
    207QS1201X

    Related Payer Policy Updates

    Specialty: Allergy/Clinical Immunology1 / 3

    10 rows

    PolicyPayerEffective Date
    Allergen Subcutaneous Immunotherapy (SCIT)Providence Health Plan2026-11-01
    Allergy Testing, Including Selected Blood, Serum and Cellular Testing and Toxicity Testing Corporate Medical Policybcbsvermont2026-11-01
    Allergy and Sensitivity Tests of Uncertain Efficacyregence2026-10-01
    Allergy Testing and InjectionsUnitedHealthcare2026-10-01
    Allergy TestingProvidence Health Plan2026-10-01
    Diagnosis of Idiopathic Environmental IntoleranceOscar Health2026-10-01
    Allergen Testingblue cross blue shield - louisiana2026-09-15
    Allergen TestingBlue Cross Blue Shield - New Mexico2026-09-04
    Allergen Immunotherapymarylandphysicianscarempc2026-09-01
    ALLERGY TESTING / IMMUNOTHERAPYpriority_health_medicare2026-09-01

    Related Codes

    86803-QUALITATIVE-OR-SEMIQUANTITATIVE-IMMUNOASSAYS-HEPATITIS-C

    CPT 86803: Hepatitis C Antibody Immunoassay in Serum

    CPT-86000-FEBRILE-AGGLUTININS-SEROLOGIC-TEST

    CPT 86000: Febrile Agglutinins (Serologic Agglutination) Test

    CPT-86001-ALLERGEN-SPECIFIC-IGG-LABORATORY-TEST

    CPT 86001: Allergen-Specific IgG Assay, Technical Component

    CPT-86003-ALLERGEN-SPECIFIC-IGE-ASSAY-TECHNICAL

    CPT 86003: Allergen‑Specific IgE Assay Using Crude Allergen Extract

    CPT-86005-MULTI-ALLERGEN-IGE-SCREENING-QUALITATIVE

    CPT 86005: Multi-Allergen Allergen-Specific IgE Screening

    CPT-86008-ALLERGEN-COMPONENT-SPECIFIC-IGE-ASSAY

    CPT 86008: Allergen Component–Specific IgE Assay

    CPT-86015-ANTI-ACTIN-SMOOTH-MUSCLE-ANTIBODY-ASMA

    CPT 86015: Actin (Smooth Muscle) Antibody (ASMA) Immunoassay

    CPT-86021-LEUKOCYTE-ANTIBODY-IDENTIFICATION-LAB-TECHNICAL

    CPT 86021: Leukocyte Antibody Identification Laboratory Test

    CPT-86022-PLATELET-ANTIBODY-IDENTIFICATION-TECHNICAL-TEST

    CPT 86022: Platelet Antibody Detection and Identification

    CPT-86023-PLATELET-ASSOCIATED-IMMUNOGLOBULIN-DETECTION

    CPT 86023: Platelet-Associated Immunoglobulin Assay

    Showing 1–10 of 199

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.